Patient compliance with drug therapy for diabetic nephropathy.
作者信息
Hughes D, Manns B
出版信息
CMAJ. 2000 May 30;162(11):1553-4.
Abstract
摘要
相似文献
1
Patient compliance with drug therapy for diabetic nephropathy.
CMAJ. 2000 May 30;162(11):1553-4.
2
3
Improving use of ACE inhibitors in diabetic nephropathy.
Wis Med J. 1996 Aug;95(8):588-9.
4
Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
Pharmacogenet Genomics. 2007 May;17(5):359-68. doi: 10.1097/01.fpc.0000236336.34175.e8.
5
ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?
J Am Soc Nephrol. 2004 May;15(5):1358-60.
6
An evidence-based review of ACE inhibitors in incipient diabetic nephropathy.
Can J Clin Pharmacol. 2000 Summer;7(2):115-9.
7
Long-term ACE inhibitor therapy in diabetic nephropathy: potential hazard?
Diabet Med. 1998 Jun;15(6):524. doi: 10.1002/(SICI)1096-9136(199806)15:6<524::AID-DIA582>3.0.CO;2-U.
8
Managing diabetic nephropathy: recent studies.
Curr Opin Nephrol Hypertens. 2006 Mar;15(2):111-6. doi: 10.1097/01.mnh.0000214768.21911.62.
9
[Recent evidence in diabetic nephropathy].
Rev Clin Esp. 2002 Nov;202(11):599-601.
10
[Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
Orv Hetil. 2003 Mar 30;144(13):613-9.
引用本文的文献
1
Treatment compliance among previously diagnosed type 2 diabetics in a rural area in Southern India.
J Family Med Prim Care. 2019 Mar;8(3):919-922. doi: 10.4103/jfmpc.jfmpc_23_19.
2
Diabetic kidney disease patients on hemodialysis: a retrospective survival analysis across different socioeconomic groups.
Clin Kidney J. 2016 Dec;9(6):833-838. doi: 10.1093/ckj/sfw069. Epub 2016 Aug 17.
3
Adherence to medication among outpatient adolescents with epilepsy.
Saudi Pharm J. 2015 Jan;23(1):33-40. doi: 10.1016/j.jsps.2014.05.003. Epub 2014 May 26.
4
Factors affecting compliance to management of diabetes in Urban Health Center of a tertiary care teaching hospital of south India.
J Nat Sci Biol Med. 2014 Jul;5(2):365-8. doi: 10.4103/0976-9668.136186.
5
Measuring the rate of therapeutic adherence among outpatients with T2DM in Egypt.
Saudi Pharm J. 2010 Oct;18(4):225-32. doi: 10.1016/j.jsps.2010.07.004. Epub 2010 Jul 30.
6
Accounting for noncompliance in pharmacoeconomic evaluations.
Pharmacoeconomics. 2001;19(12):1185-97. doi: 10.2165/00019053-200119120-00001.
本文引用的文献
1
Despite some opposition, BC pharmacists to dispense morning-after pill without prescription.
CMAJ. 2000 Mar 21;162(6):876-7.
2
3
The effect of patient charges on the utilisation of prescription medicines.
J Health Econ. 1989 Mar;8(1):109-32. doi: 10.1016/0167-6296(89)90011-8.
4
Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.
CMAJ. 1999 Jan 12;160(1):41-6.
5
Persistence with treatment for hypertension in actual practice.
CMAJ. 1999 Jan 12;160(1):31-7.
6
Failure to comply: a therapeutic dilemma and the bane of clinical trials.
J Clin Pharmacol. 1996 Aug;36(8):674-82. doi: 10.1002/j.1552-4604.1996.tb04235.x.
7
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
N Engl J Med. 1993 Nov 11;329(20):1456-62. doi: 10.1056/NEJM199311113292004.
8
Understanding and improving patient compliance.
Ann Intern Med. 1984 Feb;100(2):258-68. doi: 10.7326/0003-4819-100-2-258.
9
The demand for prescription drugs as a function of cost-sharing.
Soc Sci Med. 1985;21(10):1063-9. doi: 10.1016/0277-9536(85)90161-3.
10
Impact of an electronic medication compliance aid on long-term blood pressure control.
J Clin Pharmacol. 1992 Mar;32(3):277-83. doi: 10.1002/j.1552-4604.1992.tb03837.x.
Zotero 插件